OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025

Invite Credit Card Holder to pay

Requester Details

Credit Card Holder Details

Company Details

Message to be included

Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point the prognosis is poor. Current standard of care therapies focus on debulking surgery and platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard. The majority of patients respond well to initial first-line therapy and enter into remission, however over 80% of patients will relapse and require multiple lines of therapy.

For many years the ovarian cancer drug market has been fairly stagnant, mainly due to the high use of generics and the lack of successful development of new innovative therapies. However, with the recent approvals of Avastin and the PARP inhibitors Lynparza (olaparib), Rubraca (rucaparib), and Zejula (niraparib), the market is beginning to diversify. New understanding of the heterogeneity and biology of ovarian cancer has led to the active development of new targeted therapies, immuno-oncology (IO) drugs, and next-generation chemotherapies. A greater understanding of the tumor microenvironment is expected to occur over the forecast period, which is anticipated to further drive the successful development of new patient-specific therapies. GlobalData is predicting a total of 9 new entrants to launch over the forecast period from 2015-2025. Competition will be particularly fierce amongst PARP inhibitors as they continue to establish their place in the treatment paradigm of ovarian cancer.

Key Questions Answered

How will the ovarian cancer market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) change from 2015–2025?

What are the most promising late-stage pipeline drugs in ovarian cancer?

How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?

What are the unmet needs in ovarian cancer treatment management?

What drivers and barriers will affect ovarian cancer therapeutics sales in the 7MM over the forecast period?

Scope

Overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline ovarian cancer market revenue from 2015–2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM ovarian cancer therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ovarian cancer therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned

AB Science

AbbVie

Acerta

Aprea

Array BioPharma

AstraZeneca

Boehringer Ingelheim

Bristol-Myers Squibb

Celsion

Chugai Pharmaceutical

Clovis Oncology

Ganymed

Genentech

Gradalis

ImmunoGen

Immunovaccine

Incyte

Innate Pharma ...

AB Science

AbbVie

Acerta

Aprea

Array BioPharma

AstraZeneca

Boehringer Ingelheim

Bristol-Myers Squibb

Celsion

Chugai Pharmaceutical

Clovis Oncology

Ganymed

Genentech

Gradalis

ImmunoGen

Immunovaccine

Incyte

Innate Pharma

Janssen

Mateon Therapeutics

MedImmune

Merck & Co.

Merck KGaA

Oasmia

Oncolytics Biotech

Ono Phamaceutical

Pfizer

PharmaMar

Prima BioMed

PsiOxus Therapeutics

Roche

Sotio

Taiho Pharmaceutical

Tesaro

VentiRx

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Ovarian Cancer: Executive Summary

2.1 Dramatic ...

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Ovarian Cancer: Executive Summary

2.1 Dramatic Growth, Driven by the Establishment of Standard of Care Maintenance Therapies, Is Projected for the 7MM Ovarian Cancer Market from 2015 to 2025

2.2 AstraZeneca, Tesaro, and Clovis are Poised for a Showdown in the PARP Inhibitor Ovarian Cancer Treatment Market for BRCA+, BRCA-like, and All Comers

2.3 Roche Expected to Remain Market Leader on the Heels of Avastin-based Combinations and the 7MM’s Second Programmed Death-Ligand 1 Inhibitor, Tecentriq, to Compete with Merck KGaA/Pfizer’s First-to-Market Bavencio

2.4 Unmet Need of More Therapies for Recurrent Patients in Later Lines of Therapy, Especially Platinum-Resistant Patients, Anticipated to be Partially Fulfilled, with Opportunities Remaining

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.2 Staging Systems

4.3 Risk Factors, Symptoms, and Screening

4.4 Prognosis and Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global Trends

5.3.1 7MM Incidence Trends

5.3.2 7MM Trends in Relative Survival

5.4 Forecast Methodology

5.4.1 Sources Used Tables

5.4.2 Forecast Assumptions and Methods

5.4.3 Sources Not Used

5.5 Epidemiological Forecast for Ovarian Cancer (2015–2025)

5.5.1 Diagnosed Incident Cases of Ovarian Cancer

5.5.2 Age-Specific Diagnosed Incident Cases of Ovarian Cancer

5.5.3 Age-Standardized Diagnosed Incidence of Ovarian Cancer

5.5.4 Diagnosed Incident Cases of Primary Peritoneal Cancer

5.5.5 Five-Year Diagnosed Prevalent Cases of Ovarian Cancer and Primary Peritoneal Cancer

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Current Treatment Options

6.1 Overview

6.2 Diagnosis and Treatment

6.2.1 Diagnosis

6.2.2 Treatment Guidelines

6.3 Clinical Practice and Leading Prescribed Drugs

6.4 Product Profiles – Major Brands, Angiogenesis Inhibitors

6.4.1 Avastin (bevacizumab)

6.5 Product Profiles – Major Brands, PARP Inhibitors

6.5.1 Lynparza (olaparib)

6.5.2 Rubraca (rucaparib)

6.5.3 Zejula (niraparib)

6.6 Product Profiles – Major Brands, Next-Generation Chemotherapies

6.6.1 Yondelis (trabectedin)

6.7 Generic Chemotherapy

6.7.1 Front-Line Treatment (Adjuvant/First Line)

6.7.2 Recurrent Disease

7 Unmet Needs Assessment and Opportunity Analysis

7.1 Overview

7.2 Improved First-line Therapies

7.2.1 Unmet Need

7.2.2 Gap Analysis

7.2.3 Opportunity

7.3 Alternative Treatment Options for Platinum-Refractory/Resistant Patients

7.3.1 Unmet Need

7.3.2 Gap Analysis

7.3.3 Opportunity

7.4 Individualized Treatment Approaches

7.4.1 Unmet Need

7.4.2 Gap Analysis

7.4.3 Opportunity

7.5 Therapy Option for Histological Subtypes Beyond High-Grade Serous Ovarian Cancer

7.5.1 Unmet Need

7.5.2 Gap Analysis

7.5.3 Opportunity

7.6 An Early Stage Diagnostic for Ovarian Cancer

7.6.1 Unmet Need

7.6.2 Gap Analysis

7.6.3 Opportunity

8 Research and Development Strategies

8.1 Overview

8.1.1 Optimizing Chemotherapy

8.1.2 Targeted Therapies – A Patient Specific Approach

8.1.3 Immunotherapies – A Patient Specific Approach

8.1.4 Combination Therapies

8.1.5 Licenses and Alliances

8.2 Clinical Trial Design

8.2.1 Current Clinical Trial Endpoints

8.2.2 The Future of Clinical Trial Endpoints

8.2.3 Moving Beyond the Current Platinum Sensitive/Resistant Paradigm for Patient Recruitment in Recurrent Clinical Trials

9 Pipeline Assessment

9.1 Overview

9.2 Product Profiles – Immune Checkpoint Modulators

9.2.1 Bavencio (avelumab)

9.2.2 Opdivo (nivolumab)

9.2.3 Tecentriq (atezolizumab)

9.3 Product Profiles – Cancer Vaccines

9.3.1 Vigil (gemogenovatucel-T)

9.4 Product Profiles – Vascular Disrupting Agents

9.4.1 Fosbretabulin tromethamine

9.5 Product Profiles – PARP Inhibitors

9.5.1 Veliparib

9.6 Product Profiles – Targeted Cytotoxic Therapies (Antibody-Drug Conjugates)

9.6.1 Mirvetuximab soravtansine

9.7 Product Profiles – Next-Generation Chemotherapies

9.7.1 Opaxio (paclitaxel poliglumex)

9.7.2 Lurbinectedin

9.7.3 Apealea/Paclical (paclitaxel)

9.8 Innovative Early Stage Approaches

9.8.1 Immune Checkpoint Modulators

9.8.2 Oncolytic Viruses

9.8.3 Angiogenesis Inhibitors

9.8.4 Interleukin-12 Agonists

9.8.5 Toll-Like Receptor 8 Agonists

9.8.6 Cancer Vaccines

9.8.7 Kinase Inhibitors

9.8.8 Targeted Cytotoxic Therapies

9.8.9 P53 Agonists

9.9 Other Notable Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Products

10.2 Commercial Benchmark of Key Pipeline Therapies

10.3 Competitive Assessment

10.4 Top-Line Ten-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.4 Forecasting Methodology

11.4.1 Percentage of Drug-Treated Patients

11.4.2 Drugs Included in Each Therapeutic Class

11.4.3 Launch and Patent Expiry Dates

11.4.4 General Pricing Assumptions

11.4.5 Average Body Weight and Surface Area Across the 7MM

11.4.6 General Forecast Assumptions

11.4.7 Individual Drug Assumptions

11.4.8 Generic and Biosimilar Erosion

11.4.9 Pricing of Pipeline Agents

11.5 Primary Research

11.5.1 Physicians and Specialists Included in This Study

11.5.2 Online Survey of High-Prescribing Physicians

11.6 About the Authors

11.6.1 Analysts

11.6.2 Epidemiologist

11.6.3 Therapy Area Director

11.6.4 Global Director of Therapy Analysis and Epidemiology

11.6.5 Global Head of Healthcare

11.7 About GlobalData

11.8 Contact Us

11.9 Disclaimer

List of tables

Table 1: Ovarian Cancer: Key Metrics in the 7MM

Table 2: FIGO Guidelines: Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum

Table ...

Table 1: Ovarian Cancer: Key Metrics in the 7MM

Table 2: FIGO Guidelines: Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum

Table 3: FDA Recommendations for Screening Tests for Women and Physicians, 2016

Table 4: Risk Factors of OC

Table 5: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of OC and PPC

Table 6: 7MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of OC and PPC

Table 7: 7MM, Diagnosed Incident Cases of OC, Ages ≥18 Years, N, 2015–2025

Table 8: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015

Table 9: 7MM, Diagnosed Incident Cases of PPC, Ages ≥18 Years, N, 2015–2025

Table 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ≥18 Years, N, 2015–2025

Table 11: Treatment Guidelines for Ovarian Cancer in the 7MM

Table 12: Preferred Single Agents or Combinations and Other Potentially Active Agents for Ovarian Cancer, by Platinum-Sensitive or Platinum-Resistant Disease

Table 13: Product Profile – Avastin

Table 14: Top-Line Data Summary for the Pivotal Phase II Trials of Avastin in Ovarian Cancer

Table 15: Avastin Safety Data from GOG-0218 Study in Newly Diagnosed Ovarian Cancer

Table 16: Grade 3 or 4 AEs from GOG-0213 Study in Recurrent Platinum-Sensitive Ovarian Cancer

Table 17: Grade ≥3 AEs from AURELIA Study in Recurrent Platinum-Resistant Ovarian Cancer

Table 18: Avastin SWOT Analysis in Ovarian Cancer, 2017

Table 19: Product Profile – Lynparza

Table 20: Efficacy Data for Lynparza Tablets from SOLO2 Trial

Table 21: Efficacy Data of Lynparza from Phase III Trial in BRCA-mutated Advanced Ovarian Cancer

Table 22: Efficacy Data of Lynparza from Study 19 in Platinum-Sensitive Recurrent BRCA+ Ovarian Cancer

Table 23: Most Commonly Reported AEs, Occurring in at Least 15% of Patients in Study 19

Table 24: Lynparza SWOT Analysis in Ovarian Cancer, 2017

Table 25: Product Profile – Rubraca

Table 26: Pooled Efficacy Data of Rubraca from Study 10 and ARIEL2 in BRCA+ Ovarian Cancer

Table 27: Most Common AEs Reported in ≥20% of Patients in Study 10 and ARIEL2

Table 28: Rubraca SWOT Analysis in Ovarian Cancer, 2017

Table 29: Product Profile – Zejula

Table 30: Efficacy Data of Zejula from NOVA Study in Platinum-Sensitive Ovarian Cancer

Table 31: Summary of the Main Reported AEs in Ovarian Cancer Patients Treated with Zejula

Table 32: Zejula SWOT Analysis, Ovarian Cancer 2017

Table 33: Product Profile – Yondelis

Table 34: Efficacy Data of Yondelis from OVA-301 in Ovarian Cancer

Table 35: Most Commonly Reported Grade 3 and 4 AEs in ≥5% of Patients in OVA-301

Table 36: Yondelis SWOT Analysis in Ovarian Cancer, 2017

Table 37: Key Clinical Trials for Generic Chemotherapies in the Front-Line Setting in Ovarian Cancer

Table 38: Key Clinical Trials for Generic IP Chemotherapies in the Front-Line Setting in Ovarian Cancer

Table 39: Key Clinical Trials for Dose-Dense Chemotherapy in Ovarian Cancer

Table 40: Key Clinical Trials for Ovarian Cancer Neoadjuvant Chemotherapy Treatment

Table 41: Key Clinical Trials for Chemotherapy Combinations in Platinum-Sensitive Ovarian Cancer

Table 42: Unmet Needs and Opportunities in Ovarian Cancer

Table 43 provides an overview of the key Phase II and III clinical trials being conducted in ovarian cancer.

Table 44: Potential New Classification System for Recurrent Ovarian Cancer

Table 45: Promising Products in Clinical Development for Ovarian Cancer, 2017

Table 46: Product Profile – Bavencio

Table 47: Efficacy Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2016

Table 48: Efficacy Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2015

Table 49: Efficacy Expansion Cohort Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2015

Table 50: Safety Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2016

Table 51: Bavencio SWOT Analysis, Ovarian Cancer 2017

Table 52: Product Profile – Opdivo

Table 53: Efficacy Data for Opdivo in Platinum-Resistant Ovarian Cancer (UMIN000005714)

Table 54: Treatment-Related AEs of Special Interest in Ovarian Cancer Patients Treated with Opdivo

Table 55: Opdivo SWOT Analysis, Ovarian Cancer 2017

Table 56: Product Profile – Tecentriq

Table 57: Tecentriq SWOT Analysis, Ovarian Cancer 2017

Table 58: Product Profile – Vigil (gemogenovatucel-T)

Table 59: Efficacy Data for Vigil in Ovarian Cancer from its Ongoing Phase II Trial

Table 60: Efficacy and Response Data from a Pooled Data Analysis of Six Vigil Clinical Trials

Table 61: Vigil SWOT Analysis, Ovarian Cancer 2017

Table 62: Product Profile – Fosbretabulin Tromethamine

Table 63: Efficacy Data of GOG-01861 Trial of Fosbretabulin in Ovarian Cancer

Table 64: Grade ≥2 AEs Experienced During GOG-01861 in Recurrent Ovarian Cancer

Table 65: Fosbretabulin SWOT Analysis, Ovarian Cancer 2017

Table 66: Product Profile – Veliparib

Table 67: Top-Line Data Summary for the Pivotal Phase II Trials of Avastin in Ovarian Cancer

Table 68: AEs Associated with Veliparib in GOG-0280 Clinical Trial

Table 69: Veliparib SWOT Analysis, Ovarian Cancer 2017

Table 70: Product Profile – Mirvetuximab soravtansine

Table 71: Efficacy Data from Phase I Study of Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

Table 72: Safety Data from Phase I Study of Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

Table 73: Mirvetuximab Soravtansine SWOT Analysis, Ovarian Cancer 2017

Table 74: Product Profile – Opaxio

Table 75: Efficacy Data from GOG-0186C Study in Heavily Pretreated Ovarian Cancer

Table 76: Treatment Related AEs for Opaxio from GOG-0186C in Ovarian Cancer

Table 77: Opaxio SWOT Analysis, Ovarian Cancer 2017

Table 78: Product Profile – Lurbinectedin

Table 79: Efficacy Data from Phase II Trial of Lurbinectedin in Platinum-Resistant/Refractory Ovarian Cancer

Table 80: Lurbinectedin Treatment in Related AEs in Platinum-Resistant/Refractory Ovarian Cancer

Table 81: Lurbinectedin SWOT Analysis, Ovarian Cancer 2017

Table 82: Product Profile – Apealea

Table 83: Efficacy Data from Phase III Study of Apealea in Platinum-Sensitive Ovarian Cancer

Table 84: All Grade AEs Associated with Apealea in Platinum-Sensitive Ovarian Cancer

Table 85: Apealea SWOT Analysis, Ovarian Cancer 2017

Table 86: Other Innovative Approaches to Ovarian Cancer Management, 2017

Table 87: Ovarian Cancer-Specific Clinical Trials Involving Yervoy

Table 88: Ovarian Cancer-Specific Clinical Trials Involving Keytruda

Table 89: Ovarian Cancer-Specific Clinical Trials Involving Monalizumab

Table 90: Ovarian Cancer-Specific Clinical Trials Involving Epacadostat

Table 91: Ovarian Cancer-Specific Clinical Trials Involving Durvalumab

Table 92: Ovarian Cancer-Specific Clinical Trials Involving Reolysin

Table 93: Ovarian Cancer-Specific Clinical Trials Involving Enadenotucirev

Table 94: Efficacy of Cediranib from ICON6 Study in Relapsed Platinum-Sensitive Ovarian Cancer

Table 95: Summary of Grade ≥3 AEs During ICON6 in Platinum-Sensitive Recurrent Ovarian Cancer

Table 96: Cediranib SWOT Analysis, Ovarian Cancer 2017

Table 97: Ovarian Cancer-Specific Clinical Trials Involving GEN-1

Table 98: Ovarian Cancer-Specific Clinical Trials Involving Motolimod

Table 99: Ovarian Cancer-Specific Clinical Trials Involving CVac

Table 100: Ovarian Cancer-Specific Clinical Trials Involving DCVAC/OvCa

Table 101: Ovarian Cancer-Specific Clinical Trials Involving DPX-Survivac

Table 102: Ovarian Cancer-Specific Clinical Trials Involving Binimetinib

Table 103: Ovarian Cancer-Specific Clinical Trials Involving Vargatef

Table 104: Ovarian Cancer-Specific Clinical Trials Involving Masitinib

Table 105: Ovarian Cancer-Specific Clinical Trials Involving Acalabrutinib

Table 106: Ovarian Cancer-Specific Clinical Trials Involving IMAB-027

Table 107: Ovarian Cancer-Specific Clinical Trials Involving APR-246

Table 108: Other Notable Ovarian Cancer Products in Development, 2017

Table 109: Clinical Benchmarking of Key Marketed and Pipeline Products

Table 110: Clinical Benchmarking of Key Marketed and Pipeline Products, Continued

Table 111: Commercial Benchmarking of Key Marketed and Pipeline Products

Table 112: Commercial Benchmarking of Key Marketed and Pipeline Products, Continued

Table 113: Top-Line Sales Forecasts for Ovarian Cancer Products, 2015–2025 ($M)

Table 114: Key Events Impacting Sales for Ovarian Cancer Products, 2015–2025

Table 115: Ovarian Cancer Products Market – Drivers and Barriers, 2015–2025

Table 116: Ovarian Cancer Patient Population segmentations in the 7MM – Secondary Sources Leveraged

Table 117: Ovarian Cancer Marketed and Pipeline Products by Therapeutic Class

Table 118: Historical and Projected Launch Dates for Key Drugs in Ovarian Cancer Across the 7MM

Table 119: Patent Expiry Dates of Key Drugs in Ovarian Cancer Across the 7MM

Table 120: Average Body Weight and Surface Area Across the 7MM

Table 121: Average Cost of Therapy of Avastin in the 7MM

Table 122: Average Cost of Therapy of Lynparza in the 7MM

Table 123: Average Cost of Therapy of Rubraca in the US and 5EU

Table 124: Average Cost of Therapy of Yondelis in the 7MM

Table 125: Average Cost of Therapy of Votrient in the 7MM

Table 126: Average Cost of Therapy of Zejula in the US and 5EU

Table 127: Average Cost of Therapy of Veliparib in the 7MM

Table 128: Average Cost of Therapy of Bavencio in the 7MM

Table 129: Average Cost of Therapy of Tecentriq in the 7MM

Table 130: Average Cost of Therapy of Opdivo in the 7MM

Table 131: Average Cost of Therapy of Vigil in the 7MM

Table 132: Average Cost of Therapy of Lurbinectedin in the 7MM

Table 133: Average Cost of Therapy of Fosbretabulin in the US and 5EU

Table 134: Average Cost of Therapy of Mirvetuximab Soravtansine in the 7MM

Table 135: Average Cost of Therapy of Apealea in the US and 5EU

Table 136: High-Prescribing Physicians Surveyed, by Country

List of figures

Figure 1: 7MM Sales from Therapeutic Agents by Region, 2015 and 2025

Figure 2: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017

Figure 3 ...

Figure 1: 7MM Sales from Therapeutic Agents by Region, 2015 and 2025

Figure 2: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017

Figure 3: Selected Types of Ovarian Cancer and Other Closely Related Neoplasms

Figure 4: Risk Factors and Symptoms Suggestive of Ovarian Cancer

Figure 5: 7MM, Diagnosed Incidence Rate of OC, Cases per 100,000, All Ages, Women, 1998─2007

Figure 6: 7MM, Diagnosed Incident Cases of OC, Ages ≥18 Years, N, 2015–2025

Figure 7: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015

Figure 8: 7MM, Age-Standardized Diagnosed Incidence of OC, Ages≥18 Years, Cases per 100,000, 2015

Figure 9: 7MM, Diagnosed Incident Cases of PPC, Ages ≥18 Years, N, 2015–2025

Figure 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ≥18 Years, N, 2015–2025

Figure 11: Top-Level Treatment Flow Chart for Ovarian Cancer Patients

Figure 12: Clinical Development Program for Avastin in Ovarian Cancer

Figure 13: Clinical Development Program for Lynparza in Ovarian Cancer

Figure 14: Clinical Development Program for Rubraca in Ovarian Cancer

Figure 15: Clinical Devlopment Program for Zejula in Ovarian Cancer

Figure 16: Clinical Development Program for Yondelis in Ovarian Cancer

Figure 17: Clinical Development Program for Bavencio in Ovarian Cancer

Figure 18: Clinical Development Program for Opdivo in Ovarian Cancer

Figure 19: Clinical Development Program for Tecentriq in Ovarian Cancer

Figure 20: Clinical Development Program for Vigil in Ovarian Cancer

Figure 21: Clinical Development Program for Fosbretabulin in Ovarian Cancer

Figure 22: Clinical Development Program for Veliparib in Ovarian Cancer

Figure 23: Clinical Development Program for Mirvetuximab Soravtansine in Ovarian Cancer

Figure 24: Clinical Development Program for Opaxio in Ovarian Cancer

Figure 25: Clinical Development Program for Lurbinectedin in Ovarian Cancer

Figure 26: Clinical Development Program for Apealea in Ovarian Cancer

Figure 27: Clinical Development Program for Cediranib in Ovarian Cancer

Figure 28: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017

Figure 29: Sales for Ovarian Cancer Products by Region, 2015–2025

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports